IMMUNITYBIO INC (IBRX) Stock Fundamental Analysis
NASDAQ:IBRX - Nasdaq - US45256X1037 - Common Stock - Currency: USD
Overall IBRX gets a fundamental rating of 2 out of 10. We evaluated IBRX against 571 industry peers in the Biotechnology industry. IBRX has a bad profitability rating. Also its financial health evaluation is rather negative. IBRX is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year IBRX has reported negative net income.
IBRX had a negative operating cash flow in the past year.
IBRX had negative earnings in each of the past 5 years.
In the past 5 years IBRX always reported negative operating cash flow.
1.2 Ratios
IBRX's Return On Assets of -161.23% is on the low side compared to the rest of the industry. IBRX is outperformed by 86.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -161.23% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-101.5%
ROA(5y)-102.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IBRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IBRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IBRX has been increased compared to 1 year ago.
IBRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, IBRX has an improved debt to assets ratio.
2.2 Solvency
IBRX has an Altman-Z score of -14.19. This is a bad value and indicates that IBRX is not financially healthy and even has some risk of bankruptcy.
IBRX's Altman-Z score of -14.19 is on the low side compared to the rest of the industry. IBRX is outperformed by 81.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -14.19 |
ROIC/WACCN/A
WACC10.04%
2.3 Liquidity
IBRX has a Current Ratio of 2.68. This indicates that IBRX is financially healthy and has no problem in meeting its short term obligations.
IBRX has a Current ratio of 2.68. This is in the lower half of the industry: IBRX underperforms 70.34% of its industry peers.
IBRX has a Quick Ratio of 2.64. This indicates that IBRX is financially healthy and has no problem in meeting its short term obligations.
IBRX has a Quick ratio of 2.64. This is in the lower half of the industry: IBRX underperforms 68.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.64 |
3. Growth
3.1 Past
IBRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.14%, which is quite good.
The Revenue has grown by 1228.26% in the past year. This is a very strong growth!
IBRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 65.56% yearly.
EPS 1Y (TTM)17.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.84%
Revenue 1Y (TTM)1228.26%
Revenue growth 3Y0.65%
Revenue growth 5Y65.56%
Sales Q2Q%7346.34%
3.2 Future
IBRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.45% yearly.
Based on estimates for the next years, IBRX will show a very strong growth in Revenue. The Revenue will grow by 411.77% on average per year.
EPS Next Y27.79%
EPS Next 2Y18.12%
EPS Next 3Y19.54%
EPS Next 5Y32.45%
Revenue Next Year2852.76%
Revenue Next 2Y1537.5%
Revenue Next 3Y766.75%
Revenue Next 5Y411.77%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IBRX. In the last year negative earnings were reported.
Also next year IBRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IBRX's earnings are expected to grow with 19.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.12%
EPS Next 3Y19.54%
5. Dividend
5.1 Amount
No dividends for IBRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.42
-0.22 (-6.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners11.38%
Inst Owner Change18.86%
Ins Owners5.38%
Ins Owner Change0.46%
Market Cap2.50B
Analysts84
Price Target12.43 (263.45%)
Short Float %28.98%
Short Ratio8.88
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.65%
Min EPS beat(2)-15.34%
Max EPS beat(2)34.64%
EPS beat(4)1
Avg EPS beat(4)-23.47%
Min EPS beat(4)-90.63%
Max EPS beat(4)34.64%
EPS beat(8)3
Avg EPS beat(8)-14.85%
EPS beat(12)4
Avg EPS beat(12)-13.29%
EPS beat(16)5
Avg EPS beat(16)-16.8%
Revenue beat(2)1
Avg Revenue beat(2)22.65%
Min Revenue beat(2)-59.26%
Max Revenue beat(2)104.56%
Revenue beat(4)3
Avg Revenue beat(4)136.81%
Min Revenue beat(4)-59.26%
Max Revenue beat(4)445.1%
Revenue beat(8)7
Avg Revenue beat(8)289.49%
Revenue beat(12)10
Avg Revenue beat(12)342.66%
Revenue beat(16)13
Avg Revenue beat(16)305.53%
PT rev (1m)-14.47%
PT rev (3m)91.18%
EPS NQ rev (1m)-17.65%
EPS NQ rev (3m)-33.33%
EPS NY rev (1m)4%
EPS NY rev (3m)2.44%
Revenue NQ rev (1m)-13.63%
Revenue NQ rev (3m)-65.63%
Revenue NY rev (1m)-5.96%
Revenue NY rev (3m)47.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 340.58 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.87
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.01
BVpS-1.02
TBVpS-1.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -161.23% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-101.5%
ROA(5y)-102.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 70.81% | ||
| Cap/Sales | 173.65% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.64 | ||
| Altman-Z | -14.19 |
F-Score4
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)315.06%
Cap/Depr(5y)197.77%
Cap/Sales(3y)16646%
Cap/Sales(5y)10081.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.84%
EPS Next Y27.79%
EPS Next 2Y18.12%
EPS Next 3Y19.54%
EPS Next 5Y32.45%
Revenue 1Y (TTM)1228.26%
Revenue growth 3Y0.65%
Revenue growth 5Y65.56%
Sales Q2Q%7346.34%
Revenue Next Year2852.76%
Revenue Next 2Y1537.5%
Revenue Next 3Y766.75%
Revenue Next 5Y411.77%
EBIT growth 1Y0.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.33%
OCF growth 3YN/A
OCF growth 5YN/A